Last reviewed · How we verify

Vitamin D 2

Department of Medical Services Ministry of Public Health of Thailand · Phase 3 active Small molecule Under review

Vitamin D 2 is a Vitamin D analog Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently in Phase 3 development for Rickets, Osteomalacia. Also known as: Ergocalciferol 300,000 IU.

Vitamin D 2 is a form of vitamin D that plays a crucial role in calcium absorption and bone health.

Vitamin D2, also known as doxercalciferol, is being studied in clinical trials for various conditions, including hyperparathyroidism, kidney failure, autism spectrum disorder, nonalcoholic steatohepatitis, and preterm infants. The exact mechanism of Vitamin D2 is not specified in the provided facts, but it is being compared to placebo and other interventions in clinical trials.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameVitamin D 2
Also known asErgocalciferol 300,000 IU
SponsorDepartment of Medical Services Ministry of Public Health of Thailand
Drug classVitamin D analog
TargetVitamin D receptor
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

Vitamin D 2 is a secosteroid that acts as a hormone in the body, regulating calcium levels and bone metabolism. It does this by binding to vitamin D receptors in the intestines, kidneys, and bones, which triggers the expression of genes involved in calcium absorption and bone mineralization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vitamin D 2

What is Vitamin D 2?

Vitamin D 2 is a Vitamin D analog drug developed by Department of Medical Services Ministry of Public Health of Thailand, indicated for Rickets, Osteomalacia.

How does Vitamin D 2 work?

Vitamin D 2 is a form of vitamin D that plays a crucial role in calcium absorption and bone health.

What is Vitamin D 2 used for?

Vitamin D 2 is indicated for Rickets, Osteomalacia.

Who makes Vitamin D 2?

Vitamin D 2 is developed by Department of Medical Services Ministry of Public Health of Thailand (see full Department of Medical Services Ministry of Public Health of Thailand pipeline at /company/department-of-medical-services-ministry-of-public-health-of-thailand).

Is Vitamin D 2 also known as anything else?

Vitamin D 2 is also known as Ergocalciferol 300,000 IU.

What drug class is Vitamin D 2 in?

Vitamin D 2 belongs to the Vitamin D analog class. See all Vitamin D analog drugs at /class/vitamin-d-analog.

What development phase is Vitamin D 2 in?

Vitamin D 2 is in Phase 3.

What are the side effects of Vitamin D 2?

Common side effects of Vitamin D 2 include Hypercalcemia.

What does Vitamin D 2 target?

Vitamin D 2 targets Vitamin D receptor and is a Vitamin D analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing